{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:33:56Z","timestamp":1789702436393,"version":"4.0.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Deletion of chromosome 17p [del(17p)] is among the most adverse cytogenetic abnormalities in multiple myeloma (MM). By integrating RNA sequencing data from cells of patients with MM with genetic dependency data from MM cell lines, we identified protein kinase membrane-associated tyrosine\/threonine 1 (PKMYT1), a member of the WEE family, as a potential therapeutic target in MM cells harboring del(17p). Genetic suppression or pharmacological inhibition of PKMYT1 activity with the selective inhibitor RP-6306 triggered accumulation of DNA damage, micronucleus formation, and mitotic catastrophe, resulting in preferential cell death in del(17p) MM cells while largely sparing del(17p)\u2212 MM cells and healthy cells. RP-6306 also reduced tumor burden and extended survival in vivo in both xenograft and TP53-deficient syngeneic models. Collectively, our findings nominate PKMYT1 as an actionable target and support PKMYT1 inhibition as a biomarker-driven therapeutic strategy for patients with del(17p) or TP53-deficient MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033819","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:02:53Z","timestamp":1780556573000},"page":"1559-1571","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-4279","authenticated-orcid":false,"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Unit for Genomics in Myeloma, Institut Universitaire du Cancer, CHU Toulouse, Toulouse, France"},{"name":"3Cancer Research Center of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-6782","authenticated-orcid":false,"given":"Jian","family":"Cui","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-9822","authenticated-orcid":false,"given":"Jessica Encinas","family":"Mayoral","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Favasuli","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Talluri","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Maheo","sequence":"additional","affiliation":[{"name":"2Unit for Genomics in Myeloma, Institut Universitaire du Cancer, CHU Toulouse, Toulouse, France"},{"name":"3Cancer Research Center of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-3461","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Cerutti","sequence":"additional","affiliation":[{"name":"2Unit for Genomics in Myeloma, Institut Universitaire du Cancer, CHU Toulouse, Toulouse, France"},{"name":"3Cancer Research Center of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-6829","authenticated-orcid":false,"given":"Masood","family":"Shammas","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Primo","sequence":"additional","affiliation":[{"name":"5Vivia Biotech, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Vicente","sequence":"additional","affiliation":[{"name":"6Division of Hemato-Oncology, Center for Applied Medical Research, Cancer Center University of Navarra, Navarra Institute for Health Research, CIBERONC, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Larrayoz","sequence":"additional","affiliation":[{"name":"6Division of Hemato-Oncology, Center for Applied Medical Research, Cancer Center University of Navarra, Navarra Institute for Health Research, CIBERONC, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Mart\u00ednez-Climent","sequence":"additional","affiliation":[{"name":"6Division of Hemato-Oncology, Center for Applied Medical Research, Cancer Center University of Navarra, Navarra Institute for Health Research, CIBERONC, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil","family":"Aktas-Samur","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Kemal","family":"Samur","sequence":"additional","affiliation":[{"name":"7Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"2Unit for Genomics in Myeloma, Institut Universitaire du Cancer, CHU Toulouse, Toulouse, France"},{"name":"3Cancer Research Center of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"2Unit for Genomics in Myeloma, Institut Universitaire du Cancer, CHU Toulouse, Toulouse, France"},{"name":"3Cancer Research Center of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"8Veterans Affairs Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2026091711213299900_bib1","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026091711213299900_bib2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026091711213299900_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"2026091711213299900_bib4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026091711213299900_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026091711213299900_bib6","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"24","key":"2026091711213299900_bib7","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026091711213299900_bib8","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41467-018-06811-z","article-title":"Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"7549","key":"2026091711213299900_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nature14418","article-title":"TP53 loss creates therapeutic vulnerability in colorectal cancer","volume":"520","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"2026091711213299900_bib10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3843028\/v1","article-title":"Novel anti-B-cell maturation antigen alpha-amanitin antibody-drug conjugate HDP-101 shows superior activity to belantamab mafodotin and enhanced efficacy in deletion 17p myeloma models","author":"Singh","year":"11  2024","journal-title":"Res Sq"},{"issue":"2","key":"2026091711213299900_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/MCB.17.2.571","article-title":"The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex","volume":"17","author":"Liu","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2026091711213299900_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-2-12","article-title":"Cdc25 and Wee1: analogous opposites?","volume":"2","author":"Perry","year":"2007","journal-title":"Cell Div"},{"issue":"2","key":"2026091711213299900_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1083\/jcb.200812045","article-title":"The decision to enter mitosis: feedback and redundancy in the mitotic entry network","volume":"185","author":"Lindqvist","year":"2009","journal-title":"J Cell Biol"},{"issue":"6","key":"2026091711213299900_bib14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1078-0432.CCR-24-3571","article-title":"Myt1 kinase: an emerging cell-cycle regulator for cancer therapeutics","volume":"31","author":"Lang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026091711213299900_bib15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s44321-024-00060-y","article-title":"Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"20","key":"2026091711213299900_bib16","doi-asserted-by":"crossref","first-page":"17997","DOI":"10.1021\/acs.jmedchem.4c01619","article-title":"Targeting protein kinase, membrane-associated tyrosine\/threonine 1 (PKMYT1) for precision cancer therapy: from discovery to clinical trial","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"issue":"7907","key":"2026091711213299900_bib17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"issue":"5540","key":"2026091711213299900_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1126\/science.1065203","article-title":"Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase","volume":"294","author":"Koepp","year":"2001","journal-title":"Science"},{"issue":"12","key":"2026091711213299900_bib19","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1158\/2767-9764.CRC-23-0306","article-title":"FBXW7-loss sensitizes cells to ATR inhibition through induced mitotic catastrophe","volume":"3","author":"O'Brien","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"15","key":"2026091711213299900_bib20","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","article-title":"Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306","volume":"65","author":"Szychowski","year":"2022","journal-title":"J Med Chem"},{"issue":"3","key":"2026091711213299900_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"7155","key":"2026091711213299900_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamaria","year":"2007","journal-title":"Nature"},{"issue":"20","key":"2026091711213299900_bib23","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"7015","key":"2026091711213299900_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"issue":"6","key":"2026091711213299900_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"2","key":"2026091711213299900_bib26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/ijms25021263","article-title":"Key proteins of replication stress response and cell cycle control as cancer therapy targets","volume":"25","author":"Khamidullina","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"40","key":"2026091711213299900_bib27","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/onc.2012.504","article-title":"The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery","volume":"32","author":"Chow","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"2026091711213299900_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16614","article-title":"The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma","volume":"191","author":"Liang","year":"2020","journal-title":"Br J Haematol"},{"issue":"23","key":"2026091711213299900_bib29","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/0008-5472.CAN-19-1961","article-title":"Upregulation of Myt1 promotes acquired resistance of cancer cells to Wee1 inhibition","volume":"79","author":"Lewis","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"2026091711213299900_bib30","doi-asserted-by":"crossref","first-page":"zcad029","DOI":"10.1093\/narcan\/zcad029","article-title":"Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma","volume":"5","author":"Benada","year":"2023","journal-title":"NAR Cancer"},{"issue":"22","key":"2026091711213299900_bib31","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low-molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"2026091711213299900_bib32","doi-asserted-by":"crossref","first-page":"e013247","DOI":"10.1136\/jitc-2025-013247","article-title":"Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer","volume":"14","author":"Gao","year":"2026","journal-title":"J Immunother Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1559\/2588623\/blood_bld-2026-033819-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1559\/2588623\/blood_bld-2026-033819-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:21:42Z","timestamp":1789658502000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/12\/1559\/568862\/PKMYT1-is-a-targetable-vulnerability-in-del-17p"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033819","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,17]]},"published":{"date-parts":[[2026,9,17]]}}}